GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Strides Pharma Science Ltd (NSE:STAR) » Definitions » Gross Profit

Strides Pharma Science (NSE:STAR) Gross Profit : ₹26,798 Mil (TTM As of Dec. 2024)


View and export this data going back to 2000. Start your Free Trial

What is Strides Pharma Science Gross Profit?

Strides Pharma Science's gross profit for the three months ended in Dec. 2024 was ₹6,735 Mil. Strides Pharma Science's gross profit for the trailing twelve months (TTM) ended in Dec. 2024 was ₹26,798 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Strides Pharma Science's gross profit for the three months ended in Dec. 2024 was ₹6,735 Mil. Strides Pharma Science's Revenue for the three months ended in Dec. 2024 was ₹11,537 Mil. Therefore, Strides Pharma Science's Gross Margin % for the quarter that ended in Dec. 2024 was 58.38%.

Strides Pharma Science had a gross margin of 58.38% for the quarter that ended in Dec. 2024 => Durable competitive advantage

During the past 13 years, the highest Gross Margin % of Strides Pharma Science was 59.73%. The lowest was 45.34%. And the median was 49.78%.


Strides Pharma Science Gross Profit Historical Data

The historical data trend for Strides Pharma Science's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Strides Pharma Science Gross Profit Chart

Strides Pharma Science Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14,727.63 18,423.75 14,387.72 19,068.56 21,658.41

Strides Pharma Science Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5,370.30 6,359.93 6,670.59 7,031.89 6,735.43

Competitive Comparison of Strides Pharma Science's Gross Profit

For the Drug Manufacturers - Specialty & Generic subindustry, Strides Pharma Science's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Strides Pharma Science's Gross Profit Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Strides Pharma Science's Gross Profit distribution charts can be found below:

* The bar in red indicates where Strides Pharma Science's Gross Profit falls into.



Strides Pharma Science Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Strides Pharma Science's Gross Profit for the fiscal year that ended in Mar. 2024 is calculated as

Gross Profit (A: Mar. 2024 )=Revenue - Cost of Goods Sold
=38910.21 - 17251.8
=21,658

Strides Pharma Science's Gross Profit for the quarter that ended in Dec. 2024 is calculated as

Gross Profit (Q: Dec. 2024 )=Revenue - Cost of Goods Sold
=11536.67 - 4801.24
=6,735

Gross Profit for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹26,798 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Strides Pharma Science's Gross Margin % for the quarter that ended in Dec. 2024 is calculated as

Gross Margin % (Q: Dec. 2024 )=Gross Profit (Q: Dec. 2024 ) / Revenue (Q: Dec. 2024 )
=(Revenue - Cost of Goods Sold) / Revenue
=6,735 / 11536.67
=58.38 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Strides Pharma Science  (NSE:STAR) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Strides Pharma Science had a gross margin of 58.38% for the quarter that ended in Dec. 2024 => Durable competitive advantage


Strides Pharma Science Gross Profit Related Terms

Thank you for viewing the detailed overview of Strides Pharma Science's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Strides Pharma Science Business Description

Traded in Other Exchanges
Address
Strides House, Bannerghatta Road, Bilekahalli, Bengaluru, KA, IND, 560 076
Strides Pharma Science Ltd is a specialty and generic drug manufacturer. The company focuses on developing niche and complex pharmaceutical products across therapeutic segments for regulated and emerging markets. Strides' emerging-market plan focuses on branded generics for the treatment of chronic therapies. The company considers merger and acquisition investment as a potential component of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities. The company's reportable segment are; Pharmaceutical & Bio-pharmaceutical.

Strides Pharma Science Headlines

No Headlines